Therapeutics for fulminant hepatitis caused by enteroviruses in neonates

Research output: Contribution to journalReview articlepeer-review

Abstract

Neonatal infection with nonpolio enteroviruses (EVs) causes nonspecific febrile illnesses and even life-threatening multiorgan failure. Hepatitis, which often results in hepatic necrosis followed by disseminated intravascular coagulopathy, is one of the most severe and frequent fatal neonatal EV infection complications. Coxsackievirus B (CVB) 1–5 and many echoviruses have been most commonly identified. Neonatal EV infection treatment has usually involved initial supportive care. Studies for CVB and echovirus infection treatments were developed for more than thirty years. Intravenous immunoglobulin and pleconaril therapy was performed in some clinical trials. Additionally, other studies demonstrated antiviral and/or anti-inflammatory pathogenesis mechanisms of neonatal EV hepatitis in in vitro or in vivo models. These treatments represented promising options for the clinical practice of neonatal EV hepatitis. However, further investigation is needed to elucidate the whole therapeutic potential and safety problems.

Original languageEnglish
Article number1014823
JournalFrontiers in Pharmacology
Volume13
DOIs
Publication statusPublished - 2022 Oct 20

All Science Journal Classification (ASJC) codes

  • Pharmacology
  • Pharmacology (medical)

Fingerprint

Dive into the research topics of 'Therapeutics for fulminant hepatitis caused by enteroviruses in neonates'. Together they form a unique fingerprint.

Cite this